Nu Skin Enterprises (NYSE:NUS) Issues Q2 Earnings Guidance

Nu Skin Enterprises (NYSE:NUS) issued an update on its second quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.82-0.84 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.93. The company issued revenue guidance of $622-623 million, compared to the consensus revenue estimate of $671.81 million.Nu Skin Enterprises also updated its FY 2019 guidance to $3.20-3.35 EPS.

NUS stock opened at $39.34 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.10 and a current ratio of 1.86. Nu Skin Enterprises has a fifty-two week low of $35.03 and a fifty-two week high of $88.68. The business has a 50-day moving average price of $47.70. The firm has a market cap of $2.16 billion, a PE ratio of 11.18, a PEG ratio of 0.90 and a beta of 0.74.

Nu Skin Enterprises (NYSE:NUS) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.06. Nu Skin Enterprises had a net margin of 4.82% and a return on equity of 26.81%. The business had revenue of $623.60 million for the quarter, compared to analysts’ expectations of $615.98 million. During the same quarter last year, the company earned $0.79 EPS. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. On average, analysts expect that Nu Skin Enterprises will post 3.87 earnings per share for the current fiscal year.

NUS has been the topic of a number of analyst reports. Deutsche Bank cut shares of Hilton Hotels from a buy rating to a hold rating and set a $92.60 price objective on the stock. in a report on Wednesday, May 1st. They noted that the move was a valuation call. DA Davidson increased their price objective on shares of Commerce Bancshares to $62.00 and gave the stock a neutral rating in a report on Wednesday. Stifel Nicolaus set a $99.00 price objective on shares of C.H. Robinson Worldwide and gave the stock a hold rating in a report on Monday, March 25th. Zacks Investment Research cut shares of Inflarx from a buy rating to a hold rating in a research note on Friday, May 3rd. Finally, Bank of America lowered their target price on shares of Canopy Growth from $80.00 to $75.00 and set a buy rating on the stock in a research note on Wednesday, June 19th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $55.63.

Nu Skin Enterprises Company Profile

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.

Featured Story: Quick Ratio

Earnings History and Estimates for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with's FREE daily email newsletter.